H7T1 Aperçu des actions HUTCHMED (China) Limited, avec ses filiales, découvre, développe et commercialise des thérapies ciblées et des immunothérapies pour le cancer et les maladies immunologiques à Hong Kong et dans le monde entier. Plus de détails
Récompenses Analyse des risques Voir tous les contrôles de risques Saisissez vos pensées, vos liens et l'histoire de votre entreprise
HUTCHMED (China) Limited Concurrents Historique des prix et performances
Résumé des hausses, des baisses et des variations du cours de l'action pour la période du 1er janvier au 31 décembre 2009 HUTCHMED (China) Historique des cours de bourse Prix actuel de l'action UK£13.50 Plus haut sur 52 semaines UK£19.90 Plus bas sur 52 semaines UK£11.10 Bêta 0.74 Variation sur 1 mois -17.18% Variation sur 3 mois -12.34% Variation sur 1 an -11.18% Variation sur 3 ans -55.59% Variation sur 5 ans -38.64% Évolution depuis l'introduction en bourse -41.36%
Nouvelles et mises à jour récentes
Hutchmed (China) Limited Announces Breakthrough Therapy Designation in China for Orpathys®? and Tagrisso®? Combination in Certain Lung Cancer Patients After Disease Progression on Egfr Inhibitor Therapy Dec 12
HUTCHMED (China) Limited Announces Appointment of Chaohong Hu as Independent Non-Executive Director and Member of Technical Committee, Effective November 21, 2024 Nov 20
HUTCHMED (China) Limited Announces Positive High-Level Results from the SAVANNAH Phase II Trial Oct 16
Hutchmed (China) Limited Highlights Clinical Data to Be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer Sep 09
HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China Aug 30
HUTCHMED (China) Limited Provides Revenue Guidance for the Year 2024 Jul 31 Voir plus de mises à jour
Hutchmed (China) Limited Announces Breakthrough Therapy Designation in China for Orpathys®? and Tagrisso®? Combination in Certain Lung Cancer Patients After Disease Progression on Egfr Inhibitor Therapy Dec 12
HUTCHMED (China) Limited Announces Appointment of Chaohong Hu as Independent Non-Executive Director and Member of Technical Committee, Effective November 21, 2024 Nov 20
HUTCHMED (China) Limited Announces Positive High-Level Results from the SAVANNAH Phase II Trial Oct 16
Hutchmed (China) Limited Highlights Clinical Data to Be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer Sep 09
HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China Aug 30
HUTCHMED (China) Limited Provides Revenue Guidance for the Year 2024 Jul 31
HUTCHMED (China) Limited to Report First Half, 2024 Results on Jul 31, 2024 Jun 26
Hutchmed Highlights Publication of Phase Iii Eslim-01 Results in the Lancet Haematology Jun 19
HUTCHMED (China) Limited Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China Jun 08
HUTCHMED (China) Limited Highlights Publication of Phase III FRUTIGA Results in Nature Medicine Jun 05
HUTCHMED (China) Limited Highlights Presentations of New and Updated Data from Several Studies of Compounds Discovered by HUTCHMED At the Upcoming American Society of Clinical Oncology May 25 HUTCHMED (China) Limited Announces Executive Changes
HUTCHMED (China) Limited Initiates the RAPMichael Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China May 15
HUTCHMED (China) Limited Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naive Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui May 14
HUTCHMED (China) Limited Appoints Dr. Renu Bhatia as an Independent Non-Executive Director and a Member of Technical Committee, Effective May 13, 2024 May 09
HUTCHMED (China) Limited, Annual General Meeting, May 10, 2024 Apr 09
HUTCHMED (China) Limited Highlights Data to be Presented at AACR Congress 2024 Apr 05
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status Apr 03
HUTCHMED (China) Limited Announces Savolitinib sNDA Accepted in China for Treatment-Naive or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC Mar 28
Hutchmed Initiates Registration Stage of the Eslim-02 Phase Ii/Iii Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China Mar 22
HUTCHMED (China) Limited Provides Revenue Guidance for the Year 2024 Feb 29
Hutchmed (China) Limited Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer At Asco Plenary Series Session Feb 07
HUTCHMED (China) Limited to Report Fiscal Year 2023 Results on Feb 28, 2024 Feb 01
HUTCHMED (China) Limited Receives Elunate® (Fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer Jan 30
HUTCHMED (China) Limited Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status Jan 11
HUTCHMED (China) Limited Completes Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China Dec 13
Hutchmed (China) Limited Announces First in Human, Open-Label, Dose-Escalation Study of Erk1/2 Inhibitor Hmpl-295 in Patients with Advanced Solid Tumors Dec 01
HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA (fruquintinib) for Previously Treated Metastatic Colorectal Cancer Nov 09
HUTCHMED (China) Limited Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan Oct 01
HUTCHMED (China) Limited Announces Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer Sep 13
Hutchmed (China) Limited Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China Sep 12
HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer Aug 29
HUTCHMED (China) Limited Announces the Sovleplenib Phase III ESLIM-01 Study Met its Primary Endpoint in Primary Immune Thrombocytopenia in China Aug 21
HUTCHMED (China) Limited Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study Jul 22
HUTCHMED (China) Limited Announces Changes to Board of Directors and Technical Committee Jul 14
Hutchmed (China) Limited Initiates Phase I Study of Its Novel SHP2 Inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China Jul 12
HUTCHMED (China) Limited to Report First Half, 2023 Results on Jul 31, 2023 Jun 27 HUTCHMED (China) Limited and Takeda Announce Publication of Phase III FRESCO-2 Results in the Lancet Jun 17
Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency Jun 16
HUTCHMED (China) Limited and Takeda Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review May 31
HUTCHMED (China) Limited Announces New and Updated Clinical Data Related to HUTCHMED May 26
HUTCHMED (China) Limited Appoints Solange Peters as Independent Non-Executive Director, Member of the Technical Committee and Member of the Audit Committee May 11
HUTCHMED (China) Limited to Report Fiscal Year 2022 Results on Feb 28, 2023 Jan 31
HUTCHMED (China) Limited Announces Agreement with NHSA for Inclusion of ORPATHYS in the National Reimbursement Drug List in China Jan 19
Hutchmed Completes Patient Enrollment of Eslim-01, A Phase Iii Trial of Sovleplenib in Primary Immune Thrombocytopenia in China Jan 04
HUTCHMED Initiates Rolling Submission of Nda to U.S. Fda for Fruquintinib for the Treatment of Refractory Colorectal Cancer Dec 20
HUTCHMED (China) Limited Announces Positive Topline Result in Fruquintinib Phase III FRUTIGA Study in Second-Line Gastric Cancer in China Nov 14 Hutchmed (China) Limited Initiates Phase 2/3 Trial of Fruquintinib Oct 28
HUTCHMED (China) Limited Initiates Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China Oct 11
HUTCHMED (China) Limited Announces Summary Results of the 691-Patient, Multi-Regional Clinical Trial Sep 08
Inmagene Biopharmaceuticals and HUTCHMED (China) Limited Announce First Participant in Global Phase I Trial of IMG-004 Aug 10 HUTCHMED (China) Limited Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer
HUTCHMED (China) Limited Announces Fruquintinib Global Phase III FRESCO-2 Study in Metastatic Colorectal Cancer Aug 08
HUTCHMED (China) Limited Initiates A Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China Aug 01
HUTCHMED (China) Limited Initiates Phase I Trial of Anti-CD47 Monoclonal Antibody HMPL-A83 in Patients with Advanced Malignant Neoplasms in China Jul 16
HUTCHMED (China) Limited Highlights First Presentation of Results of the SAVANNAH Global Phase II Trial of Savolitinib plus TAGRISSO® at the 2022 WCLC Annual Meeting Jul 13
Inmagene Biopharmaceuticals and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-007 Jul 07
HUTCHMED (China) Limited to Report First Half, 2022 Results on Aug 01, 2022 Jun 08
HUTCHMED Announces TAZVERIK(R) Approved to be Used in Hainan Pilot Zone in China Jun 02
HUTCHMED (China) Limited Announces Board Changes May 18 HUTCHMED (China) Limited Provides Revenue Guidance for the Year 2022
HUTCHMED (China) Limited Receives Approval to Commercialize Elunate in Macau Mar 03
HUTCHMED (China) Limited to Report Fiscal Year 2021 Final Results on Mar 03, 2022 Feb 08
HUTCHMED Initiates Phase Ib/II Study of HMPL-453 in Combination with Chemotherapy or Toripalimab for Advanced Solid Tumors in China Feb 05
HUTCHMED (China) Limited Initiates a Phase I Trial of HMPL-653 in Patients with Advanced Malignant Solid Tumors and TGCT in China Jan 20
HUTCHMED (China) Limited Update Analysis of Ongoing International Phase I/Ib Trial of Fruquintinib Jan 19
HUTCHMED (China) Limited Receives Breakthrough Therapy Designation in China for HMPL-523 for Treatment of Primary Immune Thrombocytopenia Jan 13
HUTCHMED Initiates Phase I Study of BTK Inhibitor HMPL-760 in Patients with Previously Treated B-Cell Non-Hodgkin Lymphoma in China Jan 10
Hutchmed (China) Limited Completes Planned Enrollment of FRESCO-2, A Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer Dec 07
HUTCHMED (China) Limited and AstraZeneca PLC Initiate Sachi Phase III Trial of Orpathys® and Tagrisso® Combination in Certain Lung Cancer Patients in China After Progression on EGFR Inhibitor Therapy Nov 24
HUTCHMED Initiates SURTORI-01, a Phase III Trial of SULANDA® in Combination with TUOYI® in the Treatment of Advanced Neuroendocrine Carcinoma in China Sep 21
HUTCHMED Receives Breakthrough Therapy Designation in China for Amdizalisib (HMPL-689) for Treatment of Relapsed or Refractory Follicular Lymphoma Sep 14
HUTCHMED (China) Limited and AstraZeneca PLC Initiate SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China Sep 09
Hutchmed Initiates a Phase Ib/II Trial of Fruquintinib in Combination with Tislelizumab in Advanced Triple Negative Breast Cancer or Advanced Endometrial Cancer Aug 26
European Medicines Agency Accepts Marketing Authorization Application for Hutchmed (China) Limited's Surufatinib Jul 16
HUTCHMED (China) Limited Initiates Phase I Trials of novel ERK inhibitor HMPL 295 in Patients with Advanced Solid Tumors in China Jul 06
U.S. FDA Accepts Filing of HUTCHMED’s NDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors Jul 02
HUTCHMED (China) Limited has completed a Follow-on Equity Offering in the amount of HKD 4.1704 billion. Jun 25
HUTCHMED (China) Limited Announces Savolitinib Approval in China for Patients with Lung Cancer with MET Exon 14 Skipping Alterations Jun 24
Hutchmed (China) Limited Announces NMPA Approval of Surufatinib (Sulanda(R) in China) for Advanced Pancreatic Neuroendocrine Tumors Jun 22 Rendement pour les actionnaires H7T1 DE Pharmaceuticals DE Marché 7D -4.9% -1.7% -1.6% 1Y -11.2% -15.8% 6.8%
Voir le rapport complet des actionnaires
Rendement vs Industrie: H7T1 a dépassé le secteur German Pharmaceuticals qui a rapporté -15.8 % au cours de l'année écoulée.
Rendement vs marché: H7T1 a sous-performé le marché German qui a rapporté 6.8 % au cours de l'année écoulée.
Volatilité des prix Is H7T1's price volatile compared to industry and market? H7T1 volatility H7T1 Average Weekly Movement 6.9% Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
Cours de l'action stable: Le cours de l'action de H7T1 a été volatil au cours des 3 derniers mois.
Volatilité au fil du temps: La volatilité hebdomadaire de H7T1 ( 7% ) est restée stable au cours de l'année écoulée, mais reste supérieure à 75 % des actions de German.
À propos de l'entreprise HUTCHMED (China) Limited, avec ses filiales, découvre, développe et commercialise des thérapies ciblées et des immunothérapies pour le cancer et les maladies immunologiques à Hong Kong et dans le monde entier. La société développe le Savolitinib pour le traitement du cancer du poumon non à petites cellules (CPNPC), du carcinome papillaire des cellules rénales (CCR) et du cancer gastrique (CG) ; et le Fruquintinib, un inhibiteur pour le cancer colorectal (CCR), le cancer du sein, le cancer gastrique, le cancer de l'endomètre (CEM) à microsatellite stable, le CPNPC, le CCR, les tumeurs gastro-intestinales, le cancer du col de l'utérus et les tumeurs solides. Elle développe également le Surufatinib, qui est utilisé pour le traitement des tumeurs neuroendocrines pancréatiques (TNE), des TNE non pancréatiques, du carcinome neuroendocrine, du SCLC, du cancer des voies biliaires et des tumeurs solides ; et le Sovleplenib, qui traite les cancers hématologiques et certaines maladies immunitaires chroniques.
Afficher plus HUTCHMED (China) Limited Résumé des fondamentaux Comment les bénéfices et les revenus de HUTCHMED (China) se comparent-ils à sa capitalisation boursière ? H7T1 statistiques fondamentales Capitalisation boursière €2.49b Bénéfices(TTM) -€40.37m Recettes(TTM ) €587.53m
Bénéfices et recettes Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM) H7T1 compte de résultat (TTM ) Recettes US$610.81m Coût des recettes US$658.26m Marge brute -US$47.45m Autres dépenses -US$5.48m Les revenus -US$41.97m
Derniers bénéfices déclarés
Jun 30, 2024
Prochaine date de publication des résultats
s/o
Résultat par action (EPS) -0.049 Marge brute -7.77% Marge bénéficiaire nette -6.87% Ratio dettes/capitaux propres 10.9%
Quelles ont été les performances à long terme de H7T1?
Voir les performances historiques et les comparaisons
Analyse de l'entreprise et données financières Données Dernière mise à jour (heure UTC) Analyse de l'entreprise 2024/12/25 16:09 Cours de l'action en fin de journée 2024/12/23 00:00 Les revenus 2024/06/30 Revenus annuels 2023/12/31
Sources de données Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC . Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
Paquet Données Cadre temporel Exemple de source américaine * Finances de l'entreprise 10 ans Compte de résultat Tableau des flux de trésorerie Bilan Estimations consensuelles des analystes +3 ans Prévisions financières Objectifs de prix des analystes Prix du marché 30 ans Cours des actions Dividendes, scissions et actions Propriété 10 ans Actionnaires principaux Délits d'initiés Gestion 10 ans L'équipe dirigeante Conseil d'administration Principaux développements 10 ans
* exemple pour les titres américains, pour les titres non-américains des formulaires et sources réglementaires équivalents sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). Pour en savoir plus , cliquez ici .
Modèle d'analyse et flocon de neige Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github . Nous avons également des guides sur la façon d'utiliser nos rapports et des tutoriels sur Youtube .
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur .
Sources des analystes HUTCHMED (China) Limited est couverte par 46 analystes. 22 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
Analyste Institution Jiangqiao Tong BOCI Research Ltd. Linda Lu BOCI Research Ltd. Alec Stranahan BofA Global Research
Afficher 43 plus d'analystes 
